Isthmus Partners LLC Invests $1.62 Million in Option Care Health, Inc. (NASDAQ:OPCH)

Isthmus Partners LLC acquired a new stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 46,402 shares of the company's stock, valued at approximately $1,622,000.

A number of other large investors also recently modified their holdings of OPCH. Raymond James Financial Inc. bought a new position in Option Care Health during the fourth quarter valued at approximately $2,027,000. PNC Financial Services Group Inc. boosted its stake in shares of Option Care Health by 5.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 28,840 shares of the company's stock valued at $669,000 after purchasing an additional 1,509 shares in the last quarter. HighTower Advisors LLC grew its holdings in shares of Option Care Health by 16.7% during the 4th quarter. HighTower Advisors LLC now owns 468,082 shares of the company's stock valued at $10,860,000 after purchasing an additional 67,021 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Option Care Health by 171.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 394,019 shares of the company's stock valued at $9,141,000 after purchasing an additional 248,762 shares during the last quarter. Finally, Madison Investment Advisors LLC purchased a new position in Option Care Health in the 4th quarter worth $4,135,000. 98.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on OPCH. UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and raised their price objective for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and set a $36.00 price target on shares of Option Care Health in a research report on Wednesday, June 18th. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a research note on Thursday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $35.50.

Option Care Health Stock Performance

Option Care Health stock opened at $29.88 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82. The firm has a market cap of $4.89 billion, a P/E ratio of 24.10, a P/E/G ratio of 1.81 and a beta of 0.73. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The firm has a 50-day moving average of $31.80 and a 200-day moving average of $31.42.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. The business had revenue of $1.33 billion during the quarter, compared to analysts' expectations of $1.26 billion. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The business's revenue was up 16.3% on a year-over-year basis. During the same quarter last year, the business posted $0.26 EPS. Sell-side analysts expect that Option Care Health, Inc. will post 1.22 EPS for the current year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.